Dose optimization of extended collimators in boron neutron capture therapy.

Abstract

In this paper, we propose the design of extending collimators aimed at reducing the radiation dose received by patients with normal tissues and protecting organs at risk in Boron Neutron Capture Therapy (BNCT). Three types of extended collimators are studied: Type 1, which is a traditional design; Type 2, which is built upon Type 1 by incorporating additional polyethylene material containing lithium fluoride (PE(LiF)); Type 3, which adds lead (Pb) to Type 1. We evaluated the dose distribution characteristics of the above-extended collimators using Monte Carlo methods simulations under different configurations: in air, in a homogeneous phantom, and a humanoid phantom model. Firstly, the neutron and gamma-ray fluxes at the collimator outlet of the three designs showed no significant changes, thus it can be expected that their therapeutic effects on tumors will be similar. Then, the dose distribution outside the irradiation field was studied. The results showed that, compared with Type 1, Type 2 has a maximum reduction of 57.14% in neutron leakage dose, and Type 3 has a maximum reduction of 21.88% in gamma-ray leakage dose. This will help to reduce the radiation dose to the local skin. Finally, the doses of different organs were simulated. The results showed that the neutron dose of Type 2 was relatively low, especially for the skin, thyroid, spinal cord, and left lung, with the neutron dose reduced by approximately 20.34%, 16.18%, 26.05%, and 18.91% respectively compared to Type 1. Type 3 collimator benefits in reducing gamma-ray dose for the thyroid, esophagus, and left lung organs, with gamma-ray dose reductions of around 10.81%, 9.45%, and 10.42% respectively. This indicates that attaching PE(LiF) or Pb materials to a standard collimator can suppress the dose distribution of patient organs, which can provide valuable insights for the design of extended collimators in BNCT.